In parallel, a Phase I clinical trial of TG4050 is enrolling patients with ovarian cancer.This second trial is including patients at the time of asymptomatic relapse after surgery and first-line chemotherapy. Dr. Matthew Block, MD, PhD,...
Clinical trial information: NCT04183166.doi:10.1200/JCO.2022.40.16_suppl.2637Jean-Pierre DelordMatthew Stephen BlockChristian OttensmeierGerardo Colon-OteroChristophe Le TourneauAna LalanneCamille JametOlivier LantzKeith L. KnutsonGisele LacosteAmerican Society of Clinical OncologyJournal of Clinical Oncology...
Clinical researchPhase IEventsEurope MORE ON THIS TOPIC Clinical research Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II April 16, 2025 · 2 min read · Tristan Manalac Europe With Tariffs Looming, EU and US Phar...
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on themyvac® platform) as well as two onco...